Objective: This study aimed to determine the intravitreal concentration of VEGF in eyes with PDR and to evaluate the effects of previous PRP on its level. Methods: It was a cross-sectional study performed at the Clinical Centre University. It included 90 eyes surgically treated with PPV, divided into three groups, group A - patients with PDR with previous PRP, group B - patients with PDR without previous PRP, and group C - PPV performed due to the indication unrelated to diabetes. A vitreous sample was obtained during PPV, and the VEGF concentration was determined using an Enzyme-linked immunosorbent assay test (ELISA). Shapiro-Wilk, nonparametric tests Kruskal-Wallis, Mann-Whithney U test, ANOVA and Spearman’s correlation test were used. Results: The highest vitreous VEGF concentration was in group B - 972.96 (743.33-1149.13) and was higher than in group A - 69.22 (37.33-225.15) and in group C - 19.93 (1.15-32.17) (p<0.001). There was a positive correlation between VEGF vitreous concentration and glucose level in group A patients (Rho=0.410; p=0.027). Conclusion: As a treatment before PPV surgery, PRP showed to be effective in the reduction of VEGF levels, which also highlighted a decrease in complications during and postoperatively. Abbreviations: DRS = Diabetic Retinopathy Study, PDR = proliferative diabetic retinopathy, VEGF = vascular endothelial growth factor, PRP = pan-retinal photocoagulation, PPV = pars plana vitrectomy, HbA1c = glycosylated hemoglobin, ETDRS = Early treatment diabetic retinopathy study, ESR = erythrocyte sedimentation rate, BCVA = best corrected visual acuity, OCT = optical coherent tomography, ILM = internal limiting membrane, PHACO = phacoemulsification, IOL = intraocular lens, ELISA = Enzyme-linked immunosorbent assay test, AUC = area under the curve, DME = diabetic macular oedema, TDR = tractional retinal detachment, VMT = vitreomacular traction

A big challenge of autonomous mobility is guaranteeing safety in all possible extreme and unexpected scenarios. For the last 25 years, the sector therefore focused on improving the automation functions. Nevertheless, autonomous mobility is still not part of daily life. The 5G-Blueprint project follows an alternative approach: direct control teleoperation. This concept relies on 5G connectivity to remove the physical coupling between the human driver or sailor and the controlled vehicle or vessel. This way, automation and teleoperation can be combined as complementary technologies, assigning them to different segments of a single trajectory, realizing driverless mobility in a safe, scalable, and cost-efficient manner. However, this mode of operation brings demanding connectivity requirements, such as high uplink bandwidth, low latency and ultra-reliability at the same time, for which the potential of 5G needs to be studied and explored. In this paper, we present our performance validation strategies to pursue 5G-enhanced teleoperation in real-life environment (e.g., public roads, busy sea ports), including some initial results that we collected during the in-country piloting phase.

5G Stand Alone (SA) networks are in the process of implementation, as the today's progress of the main business services to migrate to the 5G new services communication (enhanced Mobile Broadband - eMBB, Ultra Reliable Low Latency Communications - URLLC, massive Machine Type Communications - mMTC) is estimated to slowly increase. There have been identified some key aspects responsible for the novel 5G communication adoption process, such as the complexity of the services deployment and the clear understanding of the huge potential of the technology that can further support the 5G vertical's stakeholders. This paper is representing the work of the EU funded project VITAL-5G in deploying 5G Stand Alone 3GPP Rel.16 testbeds, with enhanced network and services capabilities and 5G resources available to be offered to industries vertical's customers. The 5G solution of the testbed design is covering several aspects of the future 5G network implementation, such as services management and orchestration, automation of resources allocation, 5G network slicing (Radio Access Network, Core and Transport) and user traffic prioritization according to the service slice needs, eMBB and URLLC. An important aspect is the availability of the entire 5G ecosystem to be offered to the 5G developers and 3 rd parties for advanced and extensive trials such as Innovative Network Application (N etApps) implementations. By abstracting the complexity of underlying 5G infrastructure, reducing the time of service creation and deployment and optimizing the 5G resource usage, N etApps is a key enabler of 5G adoption.

One of the major challenges in 5G-based Cooperative Connected and Automated Mobility is to ensure continuity of a service that is deployed on the network edge and used by a moving vehicle. We propose enablers for smart cellular edges, which support service continuity in cross-border scenarios by the timely preparation of a service instance in an anticipated topologically closer target edge, and by connecting the vehicle to such service instance before the cellular handover occurs. In this paper, we use the edge data centers of a German and Austrian mobile operator to showcase two main enabling pillars for edge service continuity, i.e., i) transparent edge bridging by means of a programmable data plane to serve a vehicle from the target edge before the vehicle performs handover to a different operator, and ii) smart applications, which apply data analytics to boost orchestration decisions for target edge preparation.

Abstract Dentigerous cysts are rarely reported in young children. They are usually asymptomatic and only identified when becoming significantly large. Treatment by enucleation may damage structures like the inferior alveolar nerve, maxillary sinus, or permanent teeth, thus reducing the child's quality of life. Therefore, conservative surgical treatment such as decompression is indicated. This case report describes the treatment and subsequent complete regression of an inflammatory dentigerous cyst based on the decompression method using a customized surgical tube in a 10-year-old girl. The innervation was preserved, and permanent teeth erupted.

The management of patients with acute pulmonary embolism (aPE) depend on the risk stratification at hospital admission. It is unknown when normotensive aPE patients with some other risk factors deteriorate. Patients with objectively established acute PE diagnosis enrolled in the regional PE registry from January 2015 to December 2021, were studied in this investigation. According to European Society od Cardiology criteria patients were stratified during admission to hospital in four risk stratums. The timing for death and the main reason for death were recorded. PE-related death was defined if patient has died because of cardiac arrest or obstructive shock if there is no another possible reason for that. In the REPER registry. Among 1541 patients (514 low risk, 366 intermediate-low risk, 472 intermediate-high risk and 189 high risk) with aPE, 101 (6.6%) have died primary from aPE and 64 (4.2%) have died from other reasons during the 30-day follow-up. PE-related death across the mortality risk groups were 0.8%, 1.1%, 8.5% and 28.5% in low-risk, intermediate-low, intermediate-high and high risk PE, respectively. Median time from hospital admission to PE related death was significantly longer in intermediate-high than in high risk patients 4.5 (2.0–9.0) vs 1.0 (1.0–4.5) days, p=0.001. In the high risk group 50.9% of patients died during the first 24 hours, 9.0% in the next 24 hours and 83.0% of patients died during the first 5 days from admission. In the intermediate-high risk group 17.5% died in the first 24 hours, 12.5% died in the next 24 hours and next 25% died till the fifth day. There was no difference in timing of non PE-related death between intermediate-high and high risk patients 9.5 (6.0–18.5) vs 7.0 (3.0–23.5) days, p=0.631. There is significant delay in timing of death in intermediate-high compare to high risk PE patients, however, almost 50% of patients who died in the intermediate-high risk PE patients have died inside the first 5 days from hospital admission. Type of funding sources: None.